ICU sedation, delirium & recovery
Long-term outcomes with haloperidol versus placebo in acutely admitted adult intensive care unit (ICU) patients with delirium
Primary result · MortalityResult — go to the resultAdjusted absolute risk difference - 6.4 %-points 95% CI - 12.8%-points to - 0.2%-pointsAuthors' conclusion
In acutely admitted adult ICU patients with delirium, haloperidol treatment reduced mortality at 1-year follow-up, but did not statistically significantly improve HRQoL.
Study context
- Population
- Acutely admitted adult ICU patients with deliriumrandomised
- Participants
- 1,000 participants
- Comparison
- Haloperidol vs placebo
- Haloperidoln = 501
- Placebon = 486reference
- Primary endpoint
- Mortality and HRQoL (EQ-5D-5L index values and EQ VAS; deceased patients assigned zero)
- Follow-up
- 1 year
Methodological detailspre-planned analyses, placebo-controlled
- Pre-planned analyses
- Placebo-controlled
Primary result
Mortality
Adjusted absolute risk difference
- 6.4 %-points
95% CI - 12.8%-points to - 0.2%-points
P = 0.045
Events by treatment group
As reported in the abstract
Further findings
Health-related quality of life (HRQoL), EQ-5D-5L index values (deceased assigned 0) · 1 year
- Adjusted mean difference, EQ-5D-5L index values
- 0.04 (95% CI - 0.03 to 0.11; P = 0.091)
- Multiple imputations for missing HRQoL values
HRQoL, Euroqol (EQ) VAS (deceased assigned 0) · 1 year
- Adjusted mean difference, EQ VAS
- 3.3 (95% CI - 9.3 to 17.5; P = 0.142)
- Multiple imputations for missing HRQoL values
Original publication
Long-term outcomes with haloperidol versus placebo in acutely admitted adult ICU patients with delirium. Intensive Care Med. Published 3 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →